Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9

Benzinga Newsdesk www.benzinga.com Positive 65.3%

Neg 0% Neu 0% Pos 65.3%

Leerink Partners analyst David Risinger initiates coverage on Entera Bio (NASDAQ:ENTX) with a Outperform rating and announces Price Target of $9.